['stomach neoplasms', 'neoadjuvant therapy', 'chemoradiotherapy', 'chemotherapy']
['s-1', 'sox']

        Inclusion Criteria:

          -  Histologically or cytologically proven locally advanced gastric adenocarcinoma in
             patients staged as cT3-4N0M0 or anyTN+M0

          -  No distant metastasis in liver,lung,bone,central nervous system(CNS),no peritoneal
             transplantation

          -  No prior abdominal or pelvic radiotherapy

          -  Karnofsky performance status(KPS)≥ 70, predictive life span no less than 6 months

          -  Patients must have normal organ and marrow function as defined below: Leukocytes:
             greater than or equal to 3,000 G/L; Platelets: greater than or equal to 100,000/mm3
             .Hemoglobin:greater than or equal to 10g/L .Total bilirubin: within normal
             institutional limits; AST/ALT: less than or equal to 1.5 times the upper limit;
             Creatinine within normal upper limits

          -  Informed consent

        Exclusion Criteria:

          -  Any prior chemotherapy or other cancer treatment prior to this protocol

          -  Patients with other cancer history except cervical carcinoma in situ and non-malignant
             melanoma skin cancer

          -  With any distant metastasis in liver,lung,bone,CNS,or peritoneal transplantation

          -  History of allergic reactions attributed to similar chemical or biologic complex to
             S-1 or Xeloda or Oxaliplatin

          -  Uncontrolled illness including, but not limited to, active infection, symptomatic
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness

          -  History of myocardial infarction within the past 6 months or history of ventricular
             arrhythmia

          -  History of prior radiation to the abdomen

          -  Pregnant or lactating females
      